T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
TL;DR: Treatment with VEGFR TKIs sunitinib and sorafenib is associated with a significant increase in the risk of ATEs, and random-effects or fixed-effects models based on the heterogeneity of included studies were used.
Journal ArticleDOI
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Daniel Y.C. Heng,J. Connor Wells,Brian I. Rini,Benoit Beuselinck,Jae-Lyun Lee,Jennifer J. Knox,Georg A. Bjarnason,Sumanta K. Pal,Christian Kollmannsberger,Takeshi Yuasa,Sandy Srinivas,Frede Donskov,Aristotelis Bamias,Lori Wood,D. Scott Ernst,Neeraj Agarwal,Ulka N. Vaishampayan,Sun Young Rha,Jenny J. Kim,Toni K. Choueiri +19 more
TL;DR: Most patients benefited from tumor removal, except for those with four or more IMDC risk factors, and CN is beneficial in synchronous mRCC patients treated with targeted therapy, even after adjusting for prognostic factors.
Journal ArticleDOI
Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
Toni K. Choueiri,Anne Plantade,Paul Elson,Sylvie Negrier,Alain Ravaud,Stéphane Oudard,Ming Zhou,Brian I. Rini,Ronald M. Bukowski,Bernard Escudier +9 more
TL;DR: Patients with PRCC and ChRCC may have prolonged PFS from sunitinib and sorafenib, although clinical responses remain overall low in PRCC, and additional prospective trials with these agents in non-clear cell RCC will further clarify their use in the future.
Journal ArticleDOI
Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
Jeffrey J. Leow,William Martin-Doyle,Padma Sheila Rajagopal,Chirayu G. Patel,Erin M. Anderson,Andrew T. Rothman,Richard J. Cote,Yuksel Urun,Steven L. Chang,Toni K. Choueiri,Joaquim Bellmunt +10 more
TL;DR: An updated and improved meta-analysis of randomized trials provides further evidence of an overall survival and disease-free survival benefit in patients with MIBC receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
Journal ArticleDOI
Exercise, free radicals and oxidative stress
TL;DR: It is suggested that the free-radical-mediated damage caused by the interaction of metmyoglobin and methaemoglobin with peroxides may be an important source of oxidative stress during exercise.